DE60324309D1 - Src kinase inhibitoren zur behandlung von alzheimer krankheit - Google Patents

Src kinase inhibitoren zur behandlung von alzheimer krankheit

Info

Publication number
DE60324309D1
DE60324309D1 DE60324309T DE60324309T DE60324309D1 DE 60324309 D1 DE60324309 D1 DE 60324309D1 DE 60324309 T DE60324309 T DE 60324309T DE 60324309 T DE60324309 T DE 60324309T DE 60324309 D1 DE60324309 D1 DE 60324309D1
Authority
DE
Germany
Prior art keywords
compound
treatment
src
disease
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324309T
Other languages
English (en)
Inventor
Luc Mercken
Nicola Zambrano
Tommaso Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE60324309D1 publication Critical patent/DE60324309D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60324309T 2002-10-22 2003-10-06 Src kinase inhibitoren zur behandlung von alzheimer krankheit Expired - Lifetime DE60324309D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020292608 EP1413887A1 (de) 2002-10-22 2002-10-22 Src Kinase Inhibitoren zur Behandlung von Alzheimer Krankheit
PCT/EP2003/012063 WO2004038422A2 (en) 2002-10-22 2003-10-06 Inhibitors of src kinase for use in alzheimer's disease

Publications (1)

Publication Number Publication Date
DE60324309D1 true DE60324309D1 (de) 2008-12-04

Family

ID=32050112

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324309T Expired - Lifetime DE60324309D1 (de) 2002-10-22 2003-10-06 Src kinase inhibitoren zur behandlung von alzheimer krankheit

Country Status (9)

Country Link
US (1) US20040176313A1 (de)
EP (2) EP1413887A1 (de)
JP (1) JP2006503570A (de)
AT (1) ATE412186T1 (de)
AU (1) AU2003286144A1 (de)
DE (1) DE60324309D1 (de)
DK (1) DK1556703T3 (de)
ES (1) ES2314261T3 (de)
WO (1) WO2004038422A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
DE102005033943A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum
US8618063B2 (en) * 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287575B6 (sk) * 1999-12-22 2011-03-04 The Scripps Research Institute Farmaceutická kompozícia obsahujúca nukleovú kyselinu, použitie nukleovej kyseliny a výrobný artikel obsahujúci farmaceutickú kompozíciu
JP4317310B2 (ja) * 2000-03-09 2009-08-19 三菱化学株式会社 神経細胞死抑制作用を有する薬剤及びそのスクリーニング方法
JP2005512501A (ja) * 2000-12-06 2005-05-12 インサイト・ゲノミックス・インコーポレイテッド キナーゼおよびホスファターゼ
CA2491803A1 (en) * 2002-06-25 2003-12-31 Serono Genetics Institute S.A. Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
US7195884B2 (en) * 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases

Also Published As

Publication number Publication date
JP2006503570A (ja) 2006-02-02
WO2004038422A2 (en) 2004-05-06
ATE412186T1 (de) 2008-11-15
EP1413887A1 (de) 2004-04-28
ES2314261T3 (es) 2009-03-16
EP1556703A2 (de) 2005-07-27
AU2003286144A1 (en) 2004-05-13
US20040176313A1 (en) 2004-09-09
AU2003286144A8 (en) 2004-05-13
EP1556703B1 (de) 2008-10-22
WO2004038422A3 (en) 2004-09-02
DK1556703T3 (da) 2009-02-23

Similar Documents

Publication Publication Date Title
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
EP1485381B8 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2004071447A3 (en) Substituted azole derivatives as therapeutic agents
ATE493401T1 (de) Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
UA88257C2 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ С-α ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПОЧЕК, КОТОРЫЕ ПРИВОДЯТ К ПРОТЕИНУРИИ, И ДИАБЕТИЧЕСКИМ РЕТИНОПАТИИ, НЕВРОПАТИИ ИЛИ НЕФРОПАТИИ
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90
DE60106409D1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
ATE547104T1 (de) Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen
ATE412186T1 (de) Src kinase inhibitoren zur behandlung von alzheimer krankheit
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
WO2002092065A3 (en) Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition